NICITIA
- Gender
- Women and men
- Age
- 18 years and older
- Trial type
- Interventional
- Line of therapy
- First line
- Phase
- Phase II
What is this trial about?
The NICITIA study compares the use of immunotherapy in combination with chemotherapy to chemotherapy alone following surgery for mesothelioma (pleural cancer).
Detailed description
In this study, patients who have previously undergone surgery for pleural cancer are treated with either standard chemotherapy or standard chemotherapy combined with immunotherapy. Assignment to one of the two treatment options is determined by randomization. The study primarily investigates whether the addition of immunotherapy can delay the recurrence of the disease.
Trial sites
15 trial sites in Germany are listed. Find a site near you.
Vivantes Klinikum Neukölln, Klinik für Hämatologie, Onkologie und Palliativmedizin
12351 Berlin
Status unknownKlinikum Bremen Ost
Bremen
Status unknownStudienzentrum der Thorachirurgischen und Pneumologischen Klinik Klinken der Stadt Köln gGmbH Krankenhaus Merheim
Cologne
Status unknownKEM I Evang. Kliniken Essen-Mitte gGmbH
Henricistrasse 92, 45136 Essen
Status unknownUniversitätsklinikum Freiburg
Freiburg
Status unknownAsklepios Fachklinik München-Gauting Thorakale Onkologie
Gauting
Status unknown
This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.
- Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
- PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine
This description is based on the public trial registry (NCT04177953) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.